
Jan Paul de Boer

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/583196/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Clinicopathological features and risk factors for developing colorectal neoplasia in Hodgkin's lymphoma survivors. Digestive Endoscopy, 2022, 34, 163-170.	1.3	1
2	Reduction of GTV to high-risk CTV radiation margin in head and neck squamous cell carcinoma significantly reduced acute and late radiation-related toxicity with comparable outcomes. Radiotherapy and Oncology, 2021, 162, 170-177.	0.3	10
3	Androgen receptor signalling in macrophages promotes TREM-1-mediated prostate cancer cell line migration and invasion. Nature Communications, 2020, 11, 4498.	5.8	66
4	Chromosome 20 loss is characteristic of breast implant–associated anaplastic large cell lymphoma. Blood, 2020, 136, 2927-2932.	0.6	34
5	Diagnostic Accuracy of Stool Tests for Colorectal Cancer Surveillance in Hodgkin Lymphoma Survivors. Journal of Clinical Medicine, 2020, 9, 190.	1.0	5
6	Increased prevalence of BRCA1/2 mutations in women with macrotextured breast implants and anaplastic large cell lymphoma of the breast. Blood, 2020, 136, 1368-1372.	0.6	27
7	High prevalence of advanced colorectal neoplasia and serrated polyposis syndrome in Hodgkin lymphoma survivors. Cancer, 2019, 125, 990-999.	2.0	23
8	Baseline peripheral blood leukocytosis: Biological marker predicts outcome in oropharyngeal cancer, regardless of HPV-status. Oral Oncology, 2018, 78, 200-206.	0.8	15
9	Breast Implants and the Risk of Anaplastic Large-Cell Lymphoma in the Breast. JAMA Oncology, 2018, 4, 335.	3.4	229
10	Infradiaphragmatic irradiation and high procarbazine doses increase colorectal cancer risk in Hodgkin lymphoma survivors. British Journal of Cancer, 2017, 117, 306-314.	2.9	26
11	Colorectal cancer surveillance in Hodgkin lymphoma survivors at increased risk of therapy-related colorectal cancer: study design. BMC Cancer, 2017, 17, 112.	1.1	8
12	Late followâ€up of the randomized radiation and concomitant highâ€dose intraâ€arterial or intravenous cisplatin (RADPLAT) trial for advanced head and neck cancer. Head and Neck, 2016, 38, E488-93.	0.9	13
13	Second Cancer Risk Up to 40 Years after Treatment for Hodgkin's Lymphoma. New England Journal of Medicine, 2015, 373, 2499-2511.	13.9	474